Navigation Links
TorreyPines Therapeutics Reports First Quarter 2009 Financial Results
Date:5/1/2009

ease contains forward-looking statements or predictions. Such statements are subject to numerous known and unknown risks, uncertainties and other factors, which may cause TorreyPines' actual results to be materially different from historical results or from any results expressed or implied by such forward-looking statements. These and other risks which may cause results to differ are described in greater detail in the "Risk Factors" section of TorreyPines' annual report on Form 10-K for the year ended December 31, 2008 and TorreyPines other SEC reports. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All forward-looking statements are qualified in their entirety by this cautionary statement and TorreyPines undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof.


                                  (Tables Follow)

                          TorreyPines Therapeutics, Inc.
                      Condensed Consolidated Balance Sheets

                                   (in thousands)

                                                      March 31,  December 31,
                                                        2009        2008
                                                     (Unaudited)
    Assets
    Current assets
      Cash and cash equivalents                        $6,319     $10,864
      Prepaid expenses and other current assets           379         187
      Total current assets                              6,698      11,051

    Long-term assets                                       11          79

    Total assets                                       $6,709     $11,130

    Liabilities and stockholders' equity
    Current liabilities                         
'/>"/>
SOURCE  TorreyPines Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 

Related biology technology :

1. TorreyPines Therapeutics to Present at the NewsMakers in the Biotech Industry Conference
2. TorreyPines Therapeutics to Present at ThinkEquitys G5 Conference
3. TorreyPines Therapeutics and Eisai Co., Ltd. Extend Genetics Discovery Collaboration for Alzheimers Disease
4. TorreyPines Therapeutics to Present at ThinkEquitys ThinkClinic Conference
5. TorreyPines Therapeutics to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
6. TorreyPines Therapeutics Reports Third Quarter 2007 Results
7. TorreyPines Therapeutics to Present at Susquehanna Financial Groups Second Annual SIGnificant Options in Healthcare Conference
8. TorreyPines Therapeutics Initiates Phase II Study of Muscarinic Agonist NGX267 for Treatment of Xerostomia
9. TorreyPines Therapeutics Reports Fourth Quarter and Full Year 2007 Financial Results and Highlights
10. TorreyPines Therapeutics to Host First Quarter 2008 Results Conference Call and Webcast
11. TorreyPines Therapeutics to Present Tezampanel Phase IIb Clinical Data for Acute Migraine at 50th Annual Scientific Meeting of the American Headache Society
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/10/2009)... Corporation (Nasdaq: DNDN ) announced today that it ... of its common stock at a price to the ... to the underwriters a 30-day option to purchase up ... cover overallotments, if any. The offering is expected ... closing conditions. ,, J. P. Morgan Securities Inc. and ...
(Date:12/10/2009)... Institute (NEI), a division of the National Institutes of Health ... help fund its development of a non-invasive, passive diffusion-based treatment ... ... Salt Lake City, UT (PRWEB) December 10, 2009 ... National Institutes of Health (NIH), awarded a $2.18 million grant ...
(Date:12/10/2009)... 10 /PRNewswire-FirstCall/ - YM BioSciences Inc. (NYSE Amex: ... product development company that identifies and advances a ... stages of development, today provided an update on ... merger of Cytopia Ltd. into YM, details of ... board of directors of Cytopia has unanimously recommended ...
(Date:12/10/2009)... Vivakor, Inc. (OTC Bulletin Board: ... into an exclusive, $5 million license agreement ... ( www.regeneca.com ). The agreement exclusively ... new cutting-edge nutraceutical formulation developed by Vivakor ... formulations by Vivakor for Regeneca. Under the ...
Breaking Biology Technology:Dendreon Announces Pricing of Common Stock Offering 2Dendreon Announces Pricing of Common Stock Offering 3NEI Awards a Two-Year $2.18 Million SBIR Grant to Aciont 2NEI Awards a Two-Year $2.18 Million SBIR Grant to Aciont 3YM BIOSCIENCES OFFER FOR CYTOPIA APPROVED TO PROCEED TO SHAREHOLDER VOTE BY AUSTRALIAN COURT 2YM BIOSCIENCES OFFER FOR CYTOPIA APPROVED TO PROCEED TO SHAREHOLDER VOTE BY AUSTRALIAN COURT 3YM BIOSCIENCES OFFER FOR CYTOPIA APPROVED TO PROCEED TO SHAREHOLDER VOTE BY AUSTRALIAN COURT 4Vivakor Receives $5 Million Licensing and Purchase Agreement for Nutraceutical Products 2Vivakor Receives $5 Million Licensing and Purchase Agreement for Nutraceutical Products 3
... Innovative B.C. Technology Promises to Revolutionize Food Processing, ... EnWave Corporation (TSX-V: ENW) ("EnWave" or "the Company") ... sale of its continuous nutraREV(TM) food dehydration equipment ... one of B.C.,s largest blueberry producers. With this ...
... CUREXO Technology Corporation, pioneer in medical robotics ... orthopaedic applications, which is focused on marketing its ... be relocating its headquarters from Sacramento to Fremont ... corporate executives; the remainder of the company will ...
... Big Difference in Managing Indoor and Outdoor AllergiesATLANTA and ... nasal allergy season quickly approaches, people living with nasal ... ward-off allergens before they hit home. To help the ... the spring nasal allergy season, UCB and sanofi-aventis have ...
Other Biology Technology:EnWave Successfully Commercializes nutraREV(TM) Food Dehydration Technology 2EnWave Successfully Commercializes nutraREV(TM) Food Dehydration Technology 3EnWave Successfully Commercializes nutraREV(TM) Food Dehydration Technology 4CUREXO Technology Corporation Announces New Headquarters 2Video: Experts Unite to Help People Manage Spring Nasal Allergy Sneezin' 2Video: Experts Unite to Help People Manage Spring Nasal Allergy Sneezin' 3Video: Experts Unite to Help People Manage Spring Nasal Allergy Sneezin' 4Video: Experts Unite to Help People Manage Spring Nasal Allergy Sneezin' 5Video: Experts Unite to Help People Manage Spring Nasal Allergy Sneezin' 6
(Date:12/14/2009)... INDIANAPOLIS The most comprehensive study to date of ... regrow appendages may provide important clues to how similar ... at the School of Science at Indiana University-Purdue University ... the amputated limbs of axolotls, a type of salamander ... from any level of amputation, with the hope that ...
(Date:12/14/2009)... use as a defining feature of humans. That,s until examples ... birds and an array of other mammals. Now, a report ... a Cell Press publication, adds an octopus to the growing ... manages a behavioral trick that the researchers call stilt walking. ... coconut shell "bowls," makes its eight arms rigid, and raises ...
(Date:12/14/2009)... As good as laparoscopy is in preventing some of ... have drawbacks, including reduced blood flow and organ dysfunction. Laparoscopy ... small incisions. , By adding another ... area during laparoscopy, researchers at Duke University Medical Center have ... surgery. , The gas ethyl nitrite (ENO) helped to ...
Breaking Biology News(10 mins):IUPUI researchers tackle protein mechanisms behind limb regeneration 2Tool use in an invertebrate: The coconut-carrying octopus 2Gas improves blood flow and organ status during minimally invasive surgery 2Health and Wellness Partners Inc Says to America Feel the Surge 59568 1Health and Wellness Partners Inc Says to America Feel the Surge 59568 2Health and Wellness Partners Inc Says to America Feel the Surge 59568 3NeuroAIDS is Target of Federal Grant to Childrens Hospital 59564 1NeuroAIDS is Target of Federal Grant to Childrens Hospital 59564 2NeuroAIDS is Target of Federal Grant to Childrens Hospital 59564 3NeuroAIDS is Target of Federal Grant to Childrens Hospital 59564 4NxStage 28R 29 to Report Third Quarter 2009 Financial Results 5519 1NxStage 28R 29 to Report Third Quarter 2009 Financial Results 5519 2
... University have shown that common bacteria can deliver a ... precisely position sensors, drugs or DNA for the early ... approach represents a potential way to overcome hurdles in ... could be used as an alterative technology for gene ...
... are at double the risk of having a stroke compared ... University of Alberta. It was found that the risk of ... of treatment for Type 2 diabetes and more than doubles ... entered 12,272 subjects into a Type 2 diabetes cohort. All ...
... highly repetitive, gene-poor DNA found in regions of ... dark matter in the universe, the true nature ... of the Drosophila Heterochromatin Genome Project (DHGP), headed ... Lawrence Berkeley National Laboratory, are approaching a complete ...
Other Biology News:Bacteria ferry nanoparticles into cells for early diagnosis, treatment 2Bacteria ferry nanoparticles into cells for early diagnosis, treatment 3Exploring the dark matter of the genome 2Exploring the dark matter of the genome 3Exploring the dark matter of the genome 4Exploring the dark matter of the genome 5Exploring the dark matter of the genome 6
LECHNER AND LaVECK MEDIUMfor the clonal growth of normal human bronchial and other epithelial cells. Requires additives. With glutamine.Recommended storage condition:oC to 8oCIntended use(s):research...
...
... Quality ISO 9001:2000 Certified USDA ... Precedures Validated, SOP's Training AALAS ... for All Procedures GLP Documentation Upon Request ... stop shopping point for all your custom ...
... Materials for 15-20 enhancements when ... Western Blot Signal Enhancement System is designed to ... is an excellent tool for evaluating proteins with low ... to pre-treat membrane prior to blocking the membrane; 1x ...
Biology Products: